|
1
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takeuchi K, Choi YL, Soda M, Inamura K,
Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, et
al: Multiplex reverse transcription-PCR screening for EML4-ALK
fusion transcripts. Clin Cancer Res. 14:6618–6624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou JX, Yang H, Deng Q, Gu X, He P, Lin
Y, Zhao M, Jiang J, Chen H, Lin Y, et al: Oncogenic driver
mutations in patients with non-small-cell lung cancer at various
clinical stages. Ann Oncol. 24:1319–1325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mano H: ALKoma: A cancer subtype with a
shared target. Cancer Discov. 2:495–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mossé YP, Lim MS, Voss SD, Wilner K,
Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ,
et al: Safety and activity of crizotinib for paediatric patients
with refractory solid tumours or anaplastic large-cell lymphoma: A
Children's Oncology Group phase 1 consortium study. Lancet Oncol.
14:472–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Di Maio M, De Marinis F, Hirsch FR and
Gridelli C: Diagnostic and therapeutic issues for patients with
advanced non-small cell lung cancer harboring anaplastic lymphoma
kinase rearrangement: European vs. US perspective (Review). Int J
Oncol. 45:509–515. 2014.PubMed/NCBI
|
|
8
|
von Laffert M, Warth A, Penzel R,
Schirmacher P, Kerr KM, Elmberger G, Schildhaus HU, Büttner R,
Lopez-Rios F, Reu S, et al: Multicenter immunohistochemical
ALK-testing of non-small-cell lung cancer shows high concordance
after harmonization of techniques and interpretation criteria. J
Thorac Oncol. 9:1685–1692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McLeer-Florin A, Moro-Sibilot D, Melis A,
Salameire D, Lefebvre C, Ceccaldi F, de Fraipont F, Brambilla E and
Lantuejoul S: Dual IHC and FISH testing for ALK gene rearrangement
in lung adenocarcinomas in a routine practice: A French study. J
Thorac Oncol. 7:348–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ilie MI, Bence C, Hofman V, Long-Mira E,
Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, et al:
Discrepancies between FISH and immunohistochemistry for assessment
of the ALK status are associated with ALK ‘borderline’-positive
rearrangements or a high copy number: A potential major issue for
anti-ALK therapeutic strategies. Ann Oncol. 26:238–244. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ali G, Proietti A, Pelliccioni S, Niccoli
C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, et
al: ALK rearrangement in a large series of consecutive non-small
cell lung cancers: Comparison between a new immunohistochemical
approach and fluorescence in situ hybridization for the screening
of patients eligible for crizotinib treatment. Arch Pathol Lab Med.
138:1449–1458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wong DW, Leung EL, So KK, Tam IY, Sihoe
AD, Cheng LC, Ho KK, Au JS, Chung LP and Pik WM: The EML4-ALK
fusion gene is involved in various histologic types of lung cancers
from nonsmokerswith wild-type EGFR and KRAS. Cancer. 115:1723–1733.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soda M, Isobe K, Inoue A, Maemondo M,
Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, et
al: North-East Japan Study Group; ALK Lung Cancer Study Group: A
prospective PCR-based screening for the EML4-ALK oncogene in
non-small cell lung cancer. Clin Cancer Res. 18:5682–5689. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H,
Wang R, Ye T, Luo X, Zhang Y, et al: ALK, ROS1 and RET fusions in
1139 lung adenocarcinomas: A comprehensive study of common and
fusion pattern-specific clinicopathologic, histologic and cytologic
features. Lung Cancer. 84:121–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koivunen JP, Mermel C, Zejnullahu K,
Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas
R, et al: EML4-ALK fusion gene and efficacy of an ALK kinase
inhibitor in lung cancer. Clin Cancer Res. 14:4275–4283. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rolfo C, Passiglia F, Castiglia M, Raez
LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G,
Russo A, et al: ALK and crizotinib: After the honeymoon…what else?
Resistance mechanisms and new therapies to overcome it. Transl Lung
Cancer Res. 3:250–261. 2014.PubMed/NCBI
|
|
17
|
Teixidó C, Karachaliou N, Peg V,
Gimenez-Capitan A and Rosell R: Concordance of IHC, FISH and RT-PCR
for EML4-ALK rearrangements. Transl Lung Cancer Res. 3:70–74.
2014.PubMed/NCBI
|
|
18
|
Weickhardt AJ, Aisner DL, Franklin WA,
Varella-Garcia M, Doebele RC and Camidge DR: Diagnostic assays for
identification of anaplastic lymphoma kinase-positive non-small
cell lung cancer. Cancer. 119:1467–1477. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oxnard GR, Paweletz CP, Kuang Y, Mach SL,
O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P,
Jackman DM and Jänne PA: Noninvasive detection of response and
resistance in EGFR-mutant lung cancer using quantitative
next-generation genotyping of cell-free plasma DNA. Clin Cancer
Res. 20:1698–1705. 2014. View Article : Google Scholar : PubMed/NCBI
|
